## S5 Table. Rates of ESA Non-use among Patients with Hemoglobin ≤11.0 g/dl According to Chronic Kidney Disease G Category and Age Strata.

|       |   | 18–44 Y | 45–64 Y           | 65–74 Y | 75–84 Y | ≥85 Y            | Subtotal          |
|-------|---|---------|-------------------|---------|---------|------------------|-------------------|
| G4    | % | 83.8    | 81.0              | 85.9    | 83.0    | 87.7             | 84.5              |
| G5    | % | 54.8*   | 67.7 <sup>*</sup> | 62.4*   | 62.9*   | 77.8             | 64.9 <sup>*</sup> |
| G4+G5 | % | 68.4    | 73.9              | 75.8    | 77.3    | $85.8^{\dagger}$ | 77.5              |

Data are expressed as % of each population.

\*:p<0.05 vs. G4, †:p<0.05 vs. 45–64 Y

Abbreviations: Y, years; Hb, hemoglobin; ESA, erythropoiesis-stimulating agent